Lupin Limited
NSE: LUPIN BSE: LUPIN
NSE
2,043.40
55.40 (2.79%)
Prev Close
1988
Open Price
2022
Volume
1,611,273
Today Low / High
2021.1 / 2055
52 WK Low / High
1795.2 / 2402.9
Range
1,941 - 2,146
BSE
2,042.70
54.10 (2.72%)
Prev Close
1988.6
Open Price
2013
Volume
60,933
Today Low / High
2013 / 2055
52 WK Low / High
1774 / 2403.45
Range
1,941 - 2,145
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 2043.4 (target range: 1,941 - 2,146), reflecting a change of 55.4 (2.78672%). On the BSE, it is listed at 2042.7 (target range: 1,941 - 2,145), showing a change of 54.1 (2.72051%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
12 Sep
2,022.00
1.06%
11 Sep
1,982.00
0.30%
10 Sep
1,969.00
0.54%
09 Sep
1,937.10
1.04%
08 Sep
1,935.00
0.63%
05 Sep
1,941.90
0.10%
04 Sep
1,961.00
-1.11%
03 Sep
1,899.00
2.74%
02 Sep
1,908.00
-0.96%
01 Sep
1,887.10
0.58%
29 Aug
1,902.40
-0.39%
28 Aug
1,930.00
-1.43%
26 Aug
1,963.10
-1.96%
25 Aug
1,984.00
-0.89%
22 Aug
1,970.00
0.24%
21 Aug
1,942.20
1.05%
20 Aug
1,968.60
-1.44%
19 Aug
1,972.00
-0.17%
18 Aug
1,975.00
-0.34%
Lupin Limited Graph
Lupin Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Lupin Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 2,043.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 2,042.70 | 2,063.13 | 1,856.81 - 2,269.44 |
| 2,083.55 | 1,666.84 - 2,500.26 | ||
| 2,103.98 | 1,472.79 - 2,735.18 | ||
| Bearish Scenario | 2,042.70 | 2,022.27 | 1,820.05 - 2,224.50 |
| 2,001.85 | 1,601.48 - 2,402.22 | ||
| 1,981.42 | 1,386.99 - 2,575.84 |
Overview of Lupin Limited
ISIN
INE326A01037
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
986,673
Market Cap
933,333,167,000
Last Dividend
12
Official Website
IPO Date
2001-09-10
DCF Diff
-1,449.93
DCF
3,493
Financial Ratios Every Investor Needs
Stock Dividend of LUPIN
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-25 | July 25, 25 | 12 | 12 | 2025-07-25 | 2025-09-10 | |
| 2024-07-16 | July 16, 24 | 8 | 8 | 2024-07-16 | 2024-09-01 | |
| 2023-07-14 | July 14, 23 | 4 | 4 | 2023-07-14 | 2023-09-02 | |
| 2022-07-14 | July 14, 22 | 4 | 4 | 2022-07-15 | 2022-09-02 | |
| 2021-07-27 | July 27, 21 | 6.5 | 6.5 | 2021-07-28 | 2021-08-17 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 22,192.11 Cr | 7,455.96 Cr | 14,736.15 Cr | 0.6640 | 1,159.12 Cr | 1,531.53 Cr | 3,785.56 Cr | 3,281.62 Cr | 71.95 | 5,479.13 Cr | 0.1479 |
| 2024-03-31 | 19,656.34 Cr | 9,499.72 Cr | 10,156.62 Cr | 0.5167 | 1,526.50 Cr | 1,387.35 Cr | 2,796.64 Cr | 1,914.48 Cr | 42.05 | 3,696.94 Cr | 0.0974 |
| 2023-03-31 | 16,269.98 Cr | 9,267.53 Cr | 7,002.45 Cr | 0.4304 | 1,174.40 Cr | 1,048.78 Cr | 889.44 Cr | 430.08 Cr | 9.46 | 1,805.05 Cr | 0.0264 |
| 2022-03-31 | 16,192.79 Cr | 7,088.05 Cr | 9,104.74 Cr | 0.5623 | 1,402.36 Cr | 915.43 Cr | 1,257.99 Cr | -1,528.04 Cr | -33.65 | -438.54 Cr | -0.0944 |
| 2021-03-31 | 14,926.99 Cr | 7,693.48 Cr | 7,233.51 Cr | 0.4846 | 1,432.42 Cr | 863.40 Cr | 1,754.05 Cr | 1,216.53 Cr | 26.84 | 2,647.65 Cr | 0.0815 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,755.24 Cr | 29,204.88 Cr | 11,910.53 Cr | 17,203.5000 Cr | 5,447.77 Cr | 3,904.08 Cr | 5,476.35 Cr | 5,613.60 Cr | 0.00 Cr | 204.51 Cr | 1,301.31 Cr | 8,961.3900 Cr |
| 2024-03-31 | 1,187.60 Cr | 23,997.18 Cr | 9,623.73 Cr | 14,290.2900 Cr | 2,921.77 Cr | 1,734.17 Cr | 4,953.90 Cr | 5,494.22 Cr | 42.89 Cr | 189.40 Cr | -643.80 Cr | 8,501.5000 Cr |
| 2023-03-31 | 1,277.82 Cr | 22,955.93 Cr | 10,413.11 Cr | 12,464.5000 Cr | 4,541.52 Cr | 3,309.71 Cr | 4,491.76 Cr | 5,539.84 Cr | 63.16 Cr | 160.02 Cr | -498.44 Cr | 9,265.3700 Cr |
| 2022-03-31 | 1,089.92 Cr | 21,821.22 Cr | 9,599.24 Cr | 12,153.2700 Cr | 4,158.38 Cr | 3,068.46 Cr | 4,630.73 Cr | 5,397.30 Cr | 38.60 Cr | 134.24 Cr | -933.71 Cr | 8,276.4400 Cr |
| 2021-03-31 | 1,734.61 Cr | 23,610.44 Cr | 9,752.33 Cr | 13,803.1400 Cr | 5,129.08 Cr | 3,394.47 Cr | 4,092.01 Cr | 5,234.44 Cr | 0.00 Cr | 143.69 Cr | -2,378.94 Cr | 8,436.0900 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,999.9400 Cr | -4,171.8900 Cr | 1,731.8800 Cr | 1,317.5100 Cr | 559.9300 Cr | 1,543.6900 Cr | -1,682.4300 Cr | 3,281.6200 Cr | 2,427.7400 Cr | -365.3100 Cr | -541.2400 Cr |
| 2024-03-31 | 3,648.3600 Cr | -1,712.2000 Cr | -2,184.2100 Cr | 2,719.4600 Cr | -248.0500 Cr | 983.7600 Cr | -928.9000 Cr | 2,422.2700 Cr | -1,617.1300 Cr | -182.8000 Cr | -440.1500 Cr |
| 2023-03-31 | 1,896.9800 Cr | -1,286.7700 Cr | -337.2500 Cr | 397.6200 Cr | 273.2200 Cr | 1,264.5900 Cr | -1,499.6200 Cr | 716.4900 Cr | 172.8100 Cr | -182.5000 Cr | 195.4400 Cr |
| 2022-03-31 | 367.3100 Cr | 1,292.2300 Cr | -1,572.3200 Cr | -537.7700 Cr | 87.2200 Cr | 1,013.4400 Cr | -905.0800 Cr | -1,372.2100 Cr | -1,078.7000 Cr | -295.0900 Cr | -499.3300 Cr |
| 2021-03-31 | 1,821.7600 Cr | -1,239.5800 Cr | -1,885.2700 Cr | 1,144.1400 Cr | -1,303.0900 Cr | 926.2200 Cr | -677.6200 Cr | 1,676.4500 Cr | -1,367.7100 Cr | -272.3200 Cr | -657.4200 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 6,163.75 Cr | 1,771.93 Cr | 4,391.82 Cr | 0.7125 | 3,227.96 Cr | 1,219.03 Cr | 26.70 | 1,692.75 Cr | 0.1978 |
| 2025-03-31 | 5,667.13 Cr | 1,965.85 Cr | 3,701.28 Cr | 0.6531 | 1,012.47 Cr | 772.52 Cr | 16.94 | 1,257.22 Cr | 0.1363 |
| 2024-12-31 | 5,618.56 Cr | 1,721.55 Cr | 3,897.01 Cr | 0.6936 | 2,790.32 Cr | 855.16 Cr | 18.75 | 1,409.61 Cr | 0.1522 |
| 2024-09-30 | 5,497.01 Cr | 1,689.94 Cr | 3,807.07 Cr | 0.6926 | 1,051.36 Cr | 852.63 Cr | 18.70 | 1,382.65 Cr | 0.1551 |
| 2024-06-30 | 5,600.33 Cr | 2,963.31 Cr | 2,637.02 Cr | 0.4709 | 1,038.65 Cr | 801.31 Cr | 17.58 | 1,308.75 Cr | 0.1431 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,755.24 Cr | 1,446.20 Cr | 4,201.44 Cr | 5,502.12 Cr | 5,476.35 Cr | 16,798.58 Cr | 5,613.60 Cr | 29,204.88 Cr | 11,910.53 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 2,912.31 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -15,719.69 Cr |
| 2024-09-30 | 1,109.46 Cr | 1,498.43 Cr | 3,541.00 Cr | 5,118.98 Cr | 5,284.74 Cr | 15,020.11 Cr | 5,450.75 Cr | 25,481.96 Cr | 9,762.27 Cr |
| 2024-06-30 | -2,034.53 Cr | 4,069.06 Cr | 2,034.53 Cr | 0.00 Cr | 0.00 Cr | 2,034.53 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 1,187.60 Cr | 990.94 Cr | 2,178.54 Cr | 5,727.41 Cr | 4,953.90 Cr | 13,447.65 Cr | 5,494.22 Cr | 23,997.18 Cr | 9,623.73 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 772.52 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 855.16 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 852.63 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 801.31 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 359.43 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2010-08-27 | August 27, 10 | 5:1 |
| 2006-08-11 | August 11, 06 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,616.60 | ₹3,878,676,048,000.00 | ₹1,878,887.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,026.50 | ₹1,599,848,928,500.00 | ₹487,570.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,566.20 | ₹1,206,962,559,000.00 | ₹139,352.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,316.70 | ₹1,095,964,560,653.00 | ₹1,042,670.00 |
| Mankind Pharma Limited | MANKIND | ₹2,579.60 | ₹1,064,750,578,074.00 | ₹181,489.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹1,044.75 | ₹1,051,258,792,500.00 | ₹559,507.00 |
| Lupin Limited | LUPIN | ₹2,043.40 | ₹933,333,167,000.00 | ₹1,611,273.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,448.00 | ₹651,390,120,000.00 | ₹120,660.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,094.40 | ₹635,629,708,800.00 | ₹793,814.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,132.50 | ₹601,793,632,500.00 | ₹615,366.00 |
| Laurus Labs Limited | LAURUSLABS | ₹896.05 | ₹483,710,191,250.00 | ₹1,298,692.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹980.40 | ₹375,068,694,643.00 | ₹176,773.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,314.80 | ₹333,570,019,200.00 | ₹237,352.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,579.10 | ₹322,222,437,600.00 | ₹58,260.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,699.90 | ₹266,197,540,400.00 | ₹56,240.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,518.00 | ₹246,651,927,918.00 | ₹287,476.00 |
| Piramal Enterprises Limited | PEL | ₹1,083.70 | ₹245,650,948,600.00 | ₹565,474.00 |
| Eris Lifesciences Limited | ERIS | ₹1,675.90 | ₹228,269,311,300.00 | ₹711,885.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,003.50 | ₹225,087,500,000.00 | ₹7,058.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹16,049.00 | ₹205,907,065,100.00 | ₹157,007.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹946.50 | ₹186,046,879,500.00 | ₹132,074.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,122.30 | ₹178,761,066,300.00 | ₹82,149.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,245.60 | ₹170,691,873,520.00 | ₹78,387.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹862.20 | ₹154,428,642,000.00 | ₹287,000.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹534.35 | ₹129,656,821,400.00 | ₹1,274,862.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,243.50 | ₹103,638,353,900.00 | ₹6,067.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹926.35 | ₹83,957,850,833.00 | ₹170,096.00 |
| Strides Pharma Science Limited | STAR | ₹909.75 | ₹83,854,113,825.00 | ₹182,119.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹827.60 | ₹80,931,748,840.00 | ₹90,322.00 |
| FDC Limited | FDC | ₹463.35 | ₹75,438,013,500.00 | ₹27,055.00 |
| Innova Captab Limited | INNOVACAP | ₹859.60 | ₹49,190,549,828.00 | ₹33,571.00 |
| Suven Life Sciences Limited | SUVEN | ₹224.63 | ₹48,978,481,767.00 | ₹179,307.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹509.65 | ₹46,515,755,500.00 | ₹129,437.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹143.10 | ₹46,439,098,200.00 | ₹131,426.00 |
| Sequent Scientific Limited | SEQUENT | ₹182.51 | ₹45,688,640,850.00 | ₹212,635.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,380.30 | ₹39,367,781,700.00 | ₹11,398.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹369.25 | ₹37,027,651,500.00 | ₹37,782.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹710.75 | ₹36,048,600,325.00 | ₹42,599.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹506.40 | ₹35,653,497,120.00 | ₹17,743.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹115.76 | ₹33,978,685,520.00 | ₹10,738,156.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹677.55 | ₹32,626,065,150.00 | ₹56,274.00 |
| Hikal Limited | HIKAL | ₹257.45 | ₹31,743,842,450.00 | ₹240,530.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.90 | ₹29,534,720,600.00 | ₹3,571,211.00 |
| Indoco Remedies Limited | INDOCO | ₹299.05 | ₹27,586,734,495.00 | ₹342,407.00 |
| Alembic Limited | ALEMBICLTD | ₹103.16 | ₹26,489,631,017.00 | ₹256,891.00 |
Key Executives
Senior Vice President of Investor Relations and M&A
Mr. Ravi Agrawal
Gender: male
Year Born:
Chief Executive Officer & Executive Director
Ms. Vinita D. Gupta
Gender: female
Year Born: 1968
MD & Executive Director
Mr. Nilesh Deshbandhu Gupta
Gender: male
Year Born: 1974
Chief Technical Operations Officer
Mr. Christoph Funke
Gender: male
Year Born:
Chief Information Officer
Mr. Sreeji Gopinathan
Gender: male
Year Born:
Company Secretary & Compliance Officer
Mr. Amit Kumar Gupta
Gender: male
Year Born:
President -Global Chief Scientific Officer
Dr. Shahin Fesharaki
Gender: Not Specified
Year Born:
Vice President & Global Head of Corporate Communications
Ms. Rajalakshmi Azariah
Gender: female
Year Born:
Executive Director, Global Chief Financial Officer, CRO & Head of API Plus SBU
Mr. Ramesh Swaminathan
Gender: male
Year Born: 1965
President of Legal and Compliance of Australia, Japan & Canada Business
Dr. Sofia Mumtaz
Gender: Not Specified
Year Born:
FAQs about Lupin Limited
Who is the CEO of the company?
The CEO is Vinita D. Gupta.
What is the current market price of the stock?
The current price is ₹2,043.40.
What is the 52-week price range?
The range is ₹1795.2-2402.9.
What is the market capitalization of the company?
The market capitalization is ₹93,333.32 crores.
What is the dividend yield?
The dividend yield is 0.59%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 25.22.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Lupin Limited (ISIN: INE326A01037) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹93,333.32 crores and an average daily volume of 986,673 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹12.